Pharmacogenetic-based dosing of warfarin

Medical Letter on Drugs and Therapeutics

Volumn 50, Issue 1286, 2008, Pages 39-40

  Abramowicz, Mark ⁿ   Zuccotti, Gianna ^a   Pflomm, Jean Marie ⁿ   Morey, Susan ⁿ   Epstein, Eric J ^b   Hansten, Philip D ^c   Hirsch, Jules ^d   Juurlink, David N ^e   Kim, Richard B ^f   Mandell, Gerald L ^g   Meinertz, Hans ^h   Roden, Dan M ⁱ   Simons, F Estelle R ^j   Steigbigel, Neal H ^k   Goodstein, Donna ⁿ   Faucard, Amy ⁿ   Covey, Cynthia Macapagal ⁿ   Dalton, Vanessa K ^l   Schwartz, Lauren K ^m   Donohue, Liz ⁿ   Brown, Cheryl ⁿ   Wong, Susie ⁿ   Carbona, Gene ⁿ   Romatowski, Cristine ⁿ   Valentino, Joanne F ⁿ   Wissner Levy, Yosef ⁿ   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY OF VIRGINIA   (United States)

^h Mental Health Center Glostrup   (Denmark)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MANITOBA   (Canada)

^k NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; COLESTIPOL; COLESTYRAMINE; COTRIMOXAZOLE; CYTOCHROME P450 2C9; FLUCONAZOLE; FLUINDOSTATIN; FLUOROURACIL; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GENE PRODUCT; HYPERICUM PERFORATUM EXTRACT; METRONIDAZOLE; PARACETAMOL; PHENYTOIN; RIFAMPICIN; ROSUVASTATIN; SUCRALFATE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE C1 SUBUNIT; VORICONAZOLE; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ANTICOAGULANT THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG METABOLISM; DRUG MONITORING; DRUG SENSITIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PHARMACOGENETICS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; ALGORITHM; ARTICLE; GENETICS; METABOLISM;

ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOSIS; WARFARIN;

EID: 44649128038     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Antiplatelet and anticoagulant drugs. Treat Guidel Med Lett 2008; 6:29.
2. MK Higashi et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690.
3. NA Limdi et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83:312.
4. M Margaglione et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84:775.
5. D Voora et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005; 93:700.
6. BF Gage et and CS Eby. The genetics of vitamin K antagonists. Pharmacogenomics J 2004; 4:224.
7. MJ Rieder et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285.
8. G D'Andrea et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105:645.
9. B Gage et al. Use of pharmacogenetics and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; epub.
10. MR McClain et al. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 2008; 10:89.
11. E Millican et al. Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 2007; 110:1511.
12. PA Lenzini et al. Optimal dose adjustment in orthopaedic patients beginning warfarin therapy. Ann Pharmacother 2007; 41:1798.
13. DN Juurlink. Drug interactions with warfarin: what clinicians need to know. CMAJ 2007; 177:369.
14. UI Schwarz et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999.
15. JL Anderson et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116:2563.
16. DA Flockhart et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10:139.